| ［1］Haura EB. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies［J］. Cancer Control ,2001, 8（4）:326-336. ［2］Bai H, Zhao J, Wand SH, et al. The detection by DHPLC of EGFR mutation in tissue and peripheral blood from patients with advanced non-small cell lung cancer［J］. Chin J Tuberc Respir Dis, 2008, 31（12）:891-896. ［3］Clark GM, Zborowski DM, Santabarbara P, et al. National Cancer Institute of Canada Clinical Trials Group. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21［J］. Clin Lung Cancer,2006，7(6):389-394. ［4］Spigel DR, Lin M, ONeill V, et al. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced non-small cell lung cancer［J］.Cancer, 2008，112(12):2749-2755. ［5］Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21［J］.J Clin Oncol,2008，26(14):2350-2357. ［6］Wacker B, Nagrani T, Weinberg J, et al . Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies［J］. Clin Cancer Res,2007，13(13):3913-3921. ［7］Gridelli C, Maione P, Amoroso D, et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting［J］. Crit Rev Oncol Hematol,2008，66(2):155-162. ［8］Florescu M, Hasan B, Seymour L, et al. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21［J］.J Thorac Oncol,2008，3(6):590-598. ［9］Cedrés S, Prat A, Martínez P, et al. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib［J］. Lung Cancer, 2009，66(2):257-261. ［10］Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21［J］.J Clin Oncol, 2006， 24(24):3831-3837. ［11］Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21［J］. J Clin Oncol,2008，26(26):4268-4275. ［12］Sakurada A, Tsao MS. Predictive biomarkers for EGFR therapy［J］. Idrugs, 2009，12(1):34-38.